OnKure Therapeutics, Inc.
OKUR Nasdaq
SEC CIK 1637715
Follow OnKure Therapeutics
Weekly email: filings, results
Net income
−$17.8M
−21.4% vs same quarter last year
EPS, diluted
−$0.36
+67% vs same quarter last year
Operating cash flow
−$13.1M
−0.3% vs same quarter last year
Operating income
−$19.4M
−24.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$59.5M |
| FY24 | −$52.7M |
| FY23 | −$35.3M |
| FY22 | −$52M |
| FY21 | −$39.8M |
| FY20 | −$19.5M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$51.9M |
| FY24 | −$51.2M |
| FY23 | −$34.8M |
| FY22 | −$47.7M |
| FY21 | −$38.2M |
| FY20 | −$18.6M |
| FY19 | - |